Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$13.58 - $17.36 $1.92 Million - $2.45 Million
-141,044 Reduced 51.92%
130,627 $2.06 Million
Q4 2023

Feb 14, 2024

BUY
$10.11 - $16.54 $1.8 Million - $2.95 Million
178,261 Added 190.84%
271,671 $4.38 Million
Q3 2023

Nov 13, 2023

BUY
$12.46 - $15.48 $1.16 Million - $1.45 Million
93,410 New
93,410 $1.19 Million
Q1 2023

May 12, 2023

BUY
$14.26 - $22.1 $20,192 - $31,293
1,416 Added 10.06%
15,492 $239,000
Q4 2022

Feb 13, 2023

SELL
$14.85 - $19.04 $275,170 - $352,811
-18,530 Reduced 56.83%
14,076 $231,000
Q3 2022

Nov 15, 2022

BUY
$12.38 - $20.23 $185 - $303
15 Added 0.05%
32,606 $603,000
Q2 2022

Aug 15, 2022

BUY
$9.11 - $13.98 $136,741 - $209,839
15,010 Added 85.38%
32,591 $429,000
Q1 2022

May 16, 2022

BUY
$6.87 - $11.11 $43,816 - $70,859
6,378 Added 56.93%
17,581 $163,000
Q3 2021

Nov 15, 2021

BUY
$26.46 - $37.15 $296,431 - $416,191
11,203 New
11,203 $381,000
Q1 2021

May 14, 2021

SELL
$40.39 - $56.73 $171,455 - $240,818
-4,245 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$43.8 - $58.16 $107,222 - $142,375
-2,448 Reduced 36.58%
4,245 $218,000
Q2 2020

Aug 12, 2020

SELL
$37.05 - $65.03 $46,794 - $82,132
-1,263 Reduced 15.87%
6,693 $400,000
Q1 2020

May 13, 2020

BUY
$33.63 - $69.4 $267,560 - $552,146
7,956 New
7,956 $328,000
Q4 2019

Feb 18, 2020

SELL
$31.7 - $69.93 $315,890 - $696,852
-9,965 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$19.95 - $38.85 $198,801 - $387,140
9,965 New
9,965 $338,000

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.